Citation & Authors
Front Immunol. 2026;17:1762379.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
background
Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) share immune dysregulation, but their relative risks of inflammatory bowel disease (IBD) have not been quantified. This includes established subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), and possible subtypes, indeterminate colitis (IC) and microscopic colitis (MC). This study compared the gradient of IBD risk across AS, psoriasis (PSO), and PsA.
method
This long-term retrospective cohort study analyzed an electronic health record database. Propensity score matching adjusted for multiple confounders, and Cox proportional hazards models and log-rank tests evaluated incident IBD risk.
result
The study included 26,610 patients with AS and 322,317 with PSO during 2005–2023; 26,569 pairs were analyzed after matching. Compared with PSO, AS was significantly associated with higher risks of established IBD (HR 2.96; 95% CI 2.64–3.33), CD (3.38; 2.90–3.94), UC (2.43; 2.07–2.85), and IC (2.45; 1.33–4.51), but not MC. Higher IBD risk in AS was supported across age, sex, race, BMI, and comorbidity subgroups. Compared with the general population, AS had the highest independent risk of established IBD (4.22; 3.60–4.94), followed by PsA (HR 1.52) and PSO (1.37). AS carried 2.60 times the risk of PsA (95% CI 2.32–2.92).
Conclusion
Across the disease spectrum studied, AS had the strongest association with IBD. Compared with PSO, AS was associated with significantly higher risks of CD, UC, and IC, and a greater burden of established IBD than PsA or the general population.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
